Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837902 · ClinicalTrials.gov registry record · NA
Genetic Determinants of Response to Beta Blockade
A NA study, sponsored by Vanderbilt University.
- Completed
- Registry status
- NA
- Development phase
- 154
- Enrollment target
NCT00837902: Completed NA study, sponsored by Vanderbilt University.
NCT00837902 is a NA study that has completed, run by Vanderbilt University. The registered enrollment target is 154 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837902, a NA study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- NA
- Development phase
- 154 participants
- Enrollment target
Study Summary
The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.
Primary Outcome
Reduction in heart rate based upon genotype while exercising. Participants exercised on a recumbent bike for 2 minutes at 25W, 2 minutes at 50W, and 2 minutes at 75W twice, once before taking atenolol, and once 2.5 hours after oral administration of 25 mg of atenolol. Data points represent unadjusted mean reduction in heart rate in the 3 genotype groups.
Interventions
- DRUG Atenolol (β-blocker)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2009-01 |
| Est. Completion | 2014-12-31 |
| Phase | NA |
What the finished NCT00837902 record still lists
NCT00837902 is an interventional study that assigns participants to a tested intervention. The registered 154 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Atenolol (β-blocker) is the first listed.
NCT00837902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00837902 about?
NCT00837902 is a clinical study titled "Genetic Determinants of Response to Beta Blockade". The overall goal of this project is to determine the genetic factors contributing to interindividual differences in response to beta-blockade.
What is the current status of trial NCT00837902?
This trial is currently completed. It is a NA study. The enrollment target is 154 participants. The study started on 2009-01. Estimated completion is 2014-12-31.
What interventions are being tested in trial NCT00837902?
The interventions under investigation include: Atenolol (β-blocker) (DRUG).
Who is sponsoring clinical trial NCT00837902?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00837902's enrollment target sits among peer trials
154 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04300998 · 154 participants
Study of CAR-T Therapy in Older Patients
- NCT04597372 · 154 participants · Phase 2
Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery
- NCT05294042 · 154 participants · NA
Patient Navigators for Children's Community Mental Health Services in High Poverty Urban Communities
- NCT05512390 · 154 participants · Phase 1
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia